Clinical Research Directory

Inclusion Criteria: * Female participants aged 30 to 60 years. * Group I: Participants with Fitzpatrick skin phototypes I to VI, with at least one participant from each phototype category. Participants with facial hyperpigmentation, including post-inflammatory hyperpigmentation and solar lentigines. * Group II: Participants with moderate or greater melasma, as assessed by the modified Melasma Area and Severity Index (mMASI), and Fitzpatrick skin phototypes II to V. * Willingness to comply with all study procedures and attend scheduled on-site visits and assessments. * Willingness to comply with study procedures and be available for remote contact (telehealth) at scheduled times. * Ability to understand the study requirements, provide written informed consent, and sign the informed consent form. Exclusion Criteria: * Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study. * Use of anti-inflammatory, immunosuppressive, or antihistamine medications within 3 weeks prior to screening. * Skin conditions or marks in the study area that may interfere with the evaluation of skin reactions, including vascular malformations, scars, excessive hair growth, multiple nevi, or sunburn. * History of atopic conditions or allergy to cosmetic products. * Active skin diseases and/or lesions in the assessment area. * Immunosuppression due to medication use or active disease. * Uncontrolled endocrine disorders. * Relevant medical history or current evidence of alcohol or substance abuse. * Known history or suspected intolerance to products of the same category as the study product. * Intense sun exposure within 15 days prior to assessment. * Aesthetic or dermatological treatments within 4 weeks prior to assessment. * Any other condition that, in the investigator's opinion, may interfere with study participation or justify exclusion from the study.